Overcoming clinical resistance to EZH2 inhibition using rational epigenetic combination therapy

<p>Supplementary data for Kazansky et al, "Overcoming clinical resistance to EZH2 inhibition using rational epigenetic combination therapy" and "Epigenetic targeting of PGBD5-dependent DNA damage in SMARCB1-deficient sarcomas." Raw RNA-seq data from G401 cells can be found at the Gene Expression Omnibus (GEO) repository, accession number GSE213845. RNA-seq data from patient tumor samples has been deposited to the Database of Genotypes and Phenotypes (dbGaP), accession number phs003188.v1.p1.</p> <p>All files are labeled with their corresponding figures.</p> <p>"DESeq_processing_FINAL.R" was used for analysis of patient RNA-seq data, using "20230131_SampleTable.csv" and all "*_htseq.txt" files as input.</p> <p>"Tumor_growth_analysis_FINAL_UPDATED" was used for analysis of tumor growth kinetics using the aucVardiTest function. This was used for both of the manuscripts desscribed above.</p>